Back to Directory
Last Updated: 08/05/2026
NodThera
Cambridge
Founded 2016
NLRP3 inflammasome inhibitors for chronic inflammatory disease
NodThera is a clinical-stage biotechnology company developing potent and selective small molecule inhibitors of the NLRP3 inflammasome for diseases driven by chronic inflammation.
Its lead asset, NT-0796, is a brain-penetrant oral inhibitor in Phase Ib/IIa clinical trials for Parkinson's disease and obesity-related cardiovascular conditions.
The NLRP3 inflammasome is implicated in a broad range of inflammatory and neurodegenerative diseases, and NodThera's pipeline targets multiple indications across this biology.